SRGAP3-AS2

Across TCGA pan-cancer cohorts, SRGAP3-AS2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SRGAP3-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SRGAP3-AS2 RNA is repressed in tumor relative to normal tissue. In most cancer types SRGAP3-AS2 is over-expressed in tumor, although a few such as LUAD and KIRC show the opposite, repressed pattern.

LUAD, KIRC, and LUSC are the cancer types where SRGAP3-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRGAP3-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	−2.375	<.001	9	view →
KIRC	Male	II,III,IV	−0.138	<.001	9	view →
LUSC	Female	All	−3.276	<.001	8	view →
COAD	All	All	+0.175	<.001	6	view →
KICH	All	All	−0.130	<.001	5	view →
BRCA	Female	All	+0.365	<.001	4	view →
PRAD	All	All	+0.205	.012	2	view →
CHOL	All	All	+0.222	.016	1	view →
KIRP	Male	All	−0.058	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SRGAP3-AS2–LUAD

Open the LUAD breakdown →